Diabetes: cost of illness in Norway

BackgroundDiabetes mellitus places a considerable burden on patients in terms of morbidity and mortality and on society in terms of costs. Costs related to diabetes are expected to increase due to increasing prevalence of type 2 diabetes. The aim of this study was to estimate the health care costs attributable to type 1 and type 2 diabetes in Norway in 2005.MethodsData on inpatient hospital services, outpatient clinic visits, physician services, drugs, medical equipment, nutrition guidance, physiotherapy, acupuncture, foot therapy and indirect costs were collected from national registers and responses to a survey of 584 patients with diabetes. The study was performed with a prevalence approach. Uncertainty was explored by means of bootstrapping.ResultsWhen hospital stays with diabetes as a secondary diagnosis were excluded, the total costs were €293 million, which represents about 1.4% of the total health care expenditure. Pharmaceuticals accounted for €95 million (32%), disability pensions €48 million (16%), medical devices €40 million (14%) and hospital admissions €21 million (7%). Patient expenditures for acupuncture, physiotherapy and foot therapy were many times higher than expenditure for nutritional guidance. Indirect costs (lost production from job absenteeism) accounted for €70.1 million (24% of the €293 million) and included sick leave (€16.7 million), disability support and disability pensions (€48.2 million) and other indirect costs (€5.3 million). If all diabetes related hospital stays are included (primary- and secondary diagnosis) total costs amounts to €535 million, about 2.6% of the total health care expenditure in Norway.ConclusionsDiabetes represents a considerable burden to society in terms of health care costs and productivity losses.

[1]  B. Jönsson.  Diabetes--the cost of illness and the cost of control. An estimate for Sweden 1978. , 1983, Acta medica Scandinavica. Supplementum.

[2]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[3]  W. M. Hart,et al.  A simulation model of the cost of the incidence of IDDM in Spain , 1997, Diabetologia.

[4]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[5]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[6]  B. Jönsson,et al.  Diabetes: the cost of illness in Sweden , 1998, Journal of internal medicine.

[7]  P. Magnus,et al.  Rapid changes in the prevalence of obesity and known diabetes in an adult Norwegian population. The Nord-Trøndelag Health Surveys: 1984-1986 and 1995-1997. , 1999, Diabetes care.

[8]  C. Östenson,et al.  Direct medical costs for patients with type 2 diabetes in Sweden , 2000, Journal of internal medicine.

[9]  H. Gerstein,et al.  The economic cost of diabetes in Canada, 1998. , 2000, Diabetes care.

[10]  H. Gerstein,et al.  The Economic Cost of Diabetes in Canada, 1998 , 2002 .

[11]  Plamen Nikolov,et al.  Economic Costs of Diabetes in the U.S. in 2002 , 2003, Diabetes care.

[12]  S. Skeie,et al.  [Prevalence of diabetes mellitus in Norway]. , 2004, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[13]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[14]  B. Bolinder,et al.  Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  H. Hauner,et al.  The cost burden of diabetes mellitus: the evidence from Germany—the CoDiM Study , 2006, Diabetologia.

[16]  J. Nolan,et al.  The cost of treating type 2 diabetes (CODEIRE). , 2006, Irish medical journal.

[17]  A. Engeland,et al.  [How many and who are receiving medication for diabetes mellitus?]. , 2006, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[18]  J. Leahy.  Economic Costs of Diabetes in the U.S. in 2007 , 2008 .

[19]  C. Gip,et al.  Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005—a register‐based approach , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[20]  I. Kristiansen,et al.  Author ' s response to reviews Title : Diabetes : Cost of Illness in Norway , 2010 .

[21]  M. Engelgau,et al.  Cost-of-Illness Studies in Diabetes Mellitus , 2012, PharmacoEconomics.